Sirius Medical Secures €12 Million in Series B Funding
Sirius Medical, a Dutch company developing surgical marking and mapping solutions for cancer patients, has secured €12 million in a Series B funding round. The round was led by Holland Capital, with participation from existing investors BOM Brabant Ventures, Curie Capital, and Team Holmium, as well as new investor Norgine Ventures.
This significant investment will fuel the global expansion of Sirius Medical’s innovative Pintuition technology, a system designed to improve the accuracy and efficiency of tumor removal surgeries. Pintuition provides surgeons with real-time distance and directional navigation, guiding them to precisely locate tumors during procedures.
Pintuition: Revolutionizing Cancer Surgery Navigation
With over 100 active centers across Western Europe and the US, and more than 5,000 successful Pintuition procedures completed, Sirius Medical experienced unprecedented revenue growth in 2022. The Pintuition system holds both CE marking and FDA approval, underscoring its safety and reliability. This technology addresses a critical need in cancer surgery by enabling more precise tumor removal, potentially leading to better patient outcomes.
€12 Million Investment to Drive Global Expansion
The €12 million investment will be used to accelerate the global rollout of Pintuition and support further product development. This funding demonstrates strong confidence in Sirius Medical’s technology and its potential to significantly impact the lives of cancer patients worldwide. The company plans to leverage this investment to expand its market reach and continue innovating in the field of surgical navigation.
Leadership Perspectives on the Future of Sirius Medical
Bram Schermers, CEO of Sirius Medical, stated: “Becoming the fastest-growing company in the sector is a clear testament to the unique benefits our technology offers to both patients and physicians. This latest investment round will empower our highly talented and motivated team to further propel the global adoption of Pintuition.”
Jan Frens van Giessel of Holland Capital added: “We are excited about the market potential for surgical marker navigation. We believe that Pintuition technology, and future innovations, will significantly improve the surgery of non-palpable tumors for patients and physicians, ultimately improving the care of cancer patients.” This shared vision highlights the transformative potential of Pintuition in the fight against cancer. The €12 million investment marks a crucial step in realizing this vision.